Low dose linomide in type I juvenile diabetes of recent onset: A randomised placebo-controlled double blind trial

Diabetologia

Volumn 41, Issue 9, 1998, Pages 1040-1046

  Coutant, R ^a   Landais, P ^b   Rosilio, M ^a   Johnsen, C ^c   Lahlou, N ^a   Chatelain, P ^d   Carel, J C ^a   Ludvigsson, J ^e   Boitard, C ^a   Bougneres P F ^a  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c Pharmacia Upjohn   (Sweden)

^d HÔPITAL DEBROUSSE   (France)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Linomide; Type I diabetes

Indexed keywords

C PEPTIDE; INSULIN; ROQUINIMEX;

ADOLESCENT; ANEMIA; ARTHROPATHY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INSULIN TREATMENT; JUVENILE DIABETES MELLITUS; MALE; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYDROXYQUINOLINES; HYPOGLYCEMIC AGENTS; INSULIN; ISLETS OF LANGERHANS; MALE;

EID: 15444353015     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051028     Document Type: Article

References (44)

1. Stiller CR, Dupré J, Gent M et al (1984) Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223: 1362-1367
2. Assan R, Feutren G, Debray-Sachs M et al (1985) Metabolic and immunological effects of cyclosporin in recently diagnosed type I diabetes mellitus. Lancet 1: 67-71
3. Bougnères PF, Carel JC, Castanl L et al (1988) Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 318: 663-670
4. Bougnères PF, Landais P, Boison C et al (1990) Limited duration of the remission of insulin dependency in children with recent overt type I diabetes treated with low dose cyclosporin. Diabetes 39: 1264-1272
5. De Filippo G, Carel JC, Boitard C, Bougnères PF (1996) Long-term results of early cyclosporin therapy in juvenile IDDM. Diabetes 45: 101-104
6. Canadian-European Randomized Control Trial Group (1988) Cyclosporin-induced remission of IDDM after early intervention: association of 1 yr of cyclosporin treatment with enhanced insulin secretion. Diabetes 37: 1574-1582
7. Feutren G, Mihatsch MJ (1992) Risk factors for cyclosporin-induced nephropathy in patients with autoimmune diseases. N Engl J Med 326: 1664-1670
8. Silverstein J, MacLaren N, Riley W, Spillar R, Radjenovic D, Johnson S (1988) Immunosuppression with azathioprine and prednisone in resent-onset insulin-dependent diabetes mellitus. N Engl J Med 319: 99-604
9. Harrison LC, Coleman PG, Dean B, Baxter R, Martin FIR (1985) Increase of remission rate in newly diagnosed type I diabetic subjects treated with azathioprine. Diabetes 34: 1306-1308
10. Eisenbarth GS, Verge CF, Allen H, Rewers MJ (1993) The design of trials for prevention of IDDM. Diabetes 42: 941-947
11. Pozzili P, MacLaren NK (1993) Immunotherapy at clinical diagnosis of insulin-dependent diabetes. An approach still worth considering. Trends Endocr Metab 4: 101-105
12. Karussis DM, Lehmann D, Slavin S et al (1993) Successful treatment of chronic-relapsing experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc Natl Aead Sci USA 90: 6400-6404
13. Redondo C, Flores I, Gonzales A et al (1996) Linomide prevents the lethal effect of anti-Fas antibody and reduces Fas-mediated ceramide production in mouse hepatocytes. J Clin Invest 98: 1245-1252
14. Gross DJ, Sidi H, Weiss L, Kalland T, Rosenmann E, Slavin S (1994) Prevention of diabetes mellitus in non-obese diabetic mice by linomide, a novel immunomudulating drug. Diabetologia 37: 1195-1201
15. Karjalainen J, Samela P, Ilonen J, Surcel HM, Knip M (1989) A comparison of childhood and adult type I diabetes mellitus. N Engl J Med 320: 881-886
16. Caillat-Zucman S, Garchon HJ, Timsit J et al (1992) Age-dependent HLA genetic heterogeneity of type I insulin-dependent diabetes mellitus. J Clin Invest 90: 2242-2250
17. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 328: 1039-1057
18. Lehto M, Tuomi T, Mahtani MM et al (1997) Characterization of the MODY3 phenotype. J Clin Invest 99: 582-591
19. Bougnères PF, Landais P, Mairesse et al (1993) Improvement of diabetic control and acceptability of a three-injection insulin regimen in diabetic adolescents. Diabetes Care 16: 94-102
20. Krisher JP, Schatz D, Riley WJ et al (1993) Insulin and islet cell autoantibodies as time-dependent covariates in the development of insulin-dependent diabetes: a prospective study in relatives. J Clin Endocrinol Metab 77: 743-749
21. 65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay. Diabetes 43: 459-567
22. Kawasaki E, Yu L, Gianani R, Verge CF, Babu S, Bonifacio E, Eisenbarth GS (1997) Evaluation of islet cell antigen (ICA) 512/IA-2 autoantibody using overlapping ICA 512/IA-2 constructs. J Clin Endocrinol Metab 82: 375-380
23. Castano L, Boitard C, Bougnères PF (1988) Cyclosporin A suppresses insulin autoantibodies and heterologous insulin antibodies in type 1 diabetic children. Diabetes 37: 1049-1052
24. Kurrer MO, Pakala SV, Hanson HL, Katz JD (1997) β cell apoptosis in T cell-mediated autoimmune diabetes. Proc Natl Acad Sci 94:213-218
25. Rabinovitch A (1994) Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM: therapeutic intervention by immunostimulation? Diabetes 43: 613
26. Larson ET (1987) The mechanisms of action of the new immunomodulator ES2616 on T cell responses. Int J Immunopharmacol 9; 425
27. ras. J Immunol 157: 4721-4725
28. ras activation. J Exp Med 177: 1221
29. Karussis DM, Lehmann D, Slavin S et al (1993) Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann Neurol 34: 654-660
30. Tarkowski A, Gunnarsson K, Stälhandske T (1986) Effects of LS 2616 administration upon the autoimmune disease of (NZB/NZW) F1 hybrid mice. Immunology 59: 589-594
31. Karussis D, Lehmann D, Brenner T et al (1994) Immunomodulation of experimental autoimmune myasthenia gravis with linomide. J Neuroimmunol 55: 187-193
32. Ilbäck N, Fohlman J, Slornch S, Friman G (1989) Effects of the immunomodulator LS 2616 on lymphocyte subpopulations in murine Coxsackie virus B3 myocarditis. J Immunol 142: 3225-3228
33. Hortelano S, Diaz-Guerra MJM, Gonzalez-Garcia A et al (1997) Linomide administration to mice attemuates the induction of nitric oxide synthase elicited by lipopolysaccharide-aclivated macrophages and prevents nephritis in MRL/Mp-Ipr/Ipr Mice. J Immunol 158: 1402-1408
34. Kleinau S, Larsson P, Björk J, Holmdahl R, Klareskog L (1989) Linomide, a new immunomodulatory drug, shows different effects on homologous versus heterologous collagen-induced arthritis in rats. Clin Exp Immunol 78: 138-142
35. Björk J, Kleinau S (1989) Paradoxical effects of LS-2616 (linomide) treatment in the type II collagen arthritis model in mice. Agents Actions 27: 319-321
36. Gonzalo JA, Gonzalez-Garcia A, Kalland T, Hedlund G, Martinez AC, Kroemer G (1993) Linomide, a novel immunomodulator that inhibits death in four different models of septic shock. Eur J Immunol 23: 2372-2374
37. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H (1990) Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TFN-alpha and interleukin 1. Proc Natl Acad Sci USA 87: 968-972
38. Kalland T, Alm G, Stalhandske T (1985) Augmentation of mouse natural killer activity by LS-2616, a new immunomodulator. J Immunol 134:3956-3961
39. Bengtsson M, Simonsson B, Carlsson K et al (1992) Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator linomide after autologous bone marrow transplantation. Transplantation 53: 882-888
40. Gonzalo JA, Gonzalez-Garcia A, Kalland T, Hedlung G, Martinez C, Kroemer G (1994) Linomide inhibits programmed cell death of peripheral Tcells in vivo. Eur J Immunol 24: 48-52
41. Deeg HJ, Henslee-Downey PJ (1990) Management of acute graft-versus-host disease. Bone Marrow Transplant 6: 1
42. Andersen O, Lycke J, Tollesson PO et al (1996) Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology 47: 895-900
43. Karussis DM, Meiner Z, Lehmann D et al (1996) Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology 47: 341-346
44. Bergh J, Totterman TH, Termander B et al (1989) Marked stimulation of the immune system by linomide in cancer patients-I study. Presented at the 5th Ecco Meeting, London, Sept 3-7